Results 221 to 230 of about 70,073 (274)

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).

The Lancet Oncology, 2022
BACKGROUND Patients with metastatic castration-resistant prostate cancer have few treatment options after novel hormonal therapy (eg, abiraterone or enzalutamide).
N. Agarwal, B. McGregor, B. Maughan, T. Dorff, W. Kelly, B. Fang, R. McKay, Parminder Singh, L. Pagliaro, R. Dreicer, S. Srinivas, Y. Loriot, U. Vaishampayan, S. Goel, D. Curran, A. Panneerselvam, M. Schwickart, T. Choueiri, S. Pal   +18 more
semanticscholar   +1 more source

Castration-Resistant Prostate Cancer

Drugs, 2010
Until very recently, docetaxel was the only approved agent in castration-resistant prostate cancer (CRPC) and other effective therapeutic options are urgently needed. In recent years, several new agents with promising activity and a favourable toxicity profile have been developed and clinically investigated in the fields of hormonal, cytotoxic ...
Di Lorenzo G, Buonerba C, AUTORINO, Riccardo, De Placido S, Sternberg CN   +4 more
openaire   +4 more sources

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet Oncology, 2019
BACKGROUND Abiraterone acetate plus prednisone or prednisolone improves progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer.
Matthew R. Smith, C. Parker, F. Saad, K. Miller, B. Tombal, Q. Ng, M. Boegemann, V. Matveev, J. Piulats, L. E. Zucca, O. Karyakin, G. Kimura, N. Matsubara, W. Nahas, F. Nolè, E. Rosenbaum, A. Heidenreich, Y. Kakehi, A. Zhang, H. Krissel, M. Teufel, Junwu Shen, V. Wagner, C. Higano   +23 more
semanticscholar   +1 more source

Emerging therapies in castrate-resistant prostate cancer

Current Opinion in Oncology, 2009
Prostate cancer continues to represent a major health problem. It represents the most common cancer in US men, with an estimated 186 320 new cases diagnosed in 2008. It is the second leading cause of cancer death in men in the United States. Despite several attempts, the median survival for men with metastatic castrate-resistant prostate cancer is 1-2 ...
Kiran, Lassi, Nancy A, Dawson
openaire   +2 more sources

Management of nonmetastatic castration-resistant prostate cancer

Current Opinion in Supportive & Palliative Care, 2018
Purpose of review The widespread use of prostate-specific antigen (PSA) resulted in stage migration of prostate cancer where androgen deprivation therapy (ADT) is administered for biochemical recurrence in patients following primary treatment.
Samer L, Traboulsi, Fred, Saad
openaire   +2 more sources

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

European Urology, 2019
CONTEXT Introduction of novel agents for the management of advanced prostate cancer provides a range of treatment options with notable benefits for men with metastatic castration-resistant prostate cancer (mCRPC).
P. Nuhn, J. D. de Bono, K. Fizazi, S. Freedland, M. Grilli, P. Kantoff, G. Sonpavde, C. Sternberg, S. Yegnasubramanian, E. Antonarakis   +9 more
semanticscholar   +1 more source

[Metastatic castration-resistant prostate cancer].

Der Pathologe, 2021
Metastatic castration-resistant prostate cancer (mCRPC) is considered as the final stage of the disease with limited therapeutic options to date. In this article, we review recent histopathologic and molecular pathologic findings that may expand our understanding of the disease and may lay, or have already laid the groundwork for the development of ...
Vanessa, Henriques, Mike, Wenzel, Melanie-Christin, Demes, Jens, Köllermann   +3 more
openaire   +1 more source

The hallmarks of castration-resistant prostate cancers

Cancer Treatment Reviews, 2015
Prostate cancer has become a real public health issue in industrialized countries, mainly due to patients' relapse by castration-refractory disease after androgen ablation. Castration-resistant prostate cancer is an incurable and highly aggressive terminal stage of prostate cancer, seriously jeopardizing the patient's quality of life and lifespan.
Maria, Katsogiannou, Hajer, Ziouziou, Sara, Karaki, Claudia, Andrieu, Marie, Henry de Villeneuve, Palma, Rocchi   +5 more
openaire   +2 more sources

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.

European Urology, 2019
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is increasingly being used in metastatic castration-resistant prostate cancer (mCRPC).
M. Heck, R. Tauber, S. Schwaiger, M. Retz, C. D’Alessandria, T. Maurer, A. Gafita, H. Wester, J. Gschwend, W. Weber, M. Schwaiger, K. Knorr, M. Eiber   +12 more
semanticscholar   +1 more source

New therapies for castrate-resistant prostate cancer

Expert Opinion on Pharmacotherapy, 2011
Prostate cancer is the second leading cause of cancer death in men in the USA, and most of these deaths will occur as a result of castrate-resistant prostate cancer (CRPC) that has progressed despite androgen deprivation therapy. There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression ...
Stephen B, Williams, Aaron H, Lay, Clayton S, Lau, David Y, Josephson, Timothy G, Wilson, Toni K, Choueiri, Sumanta K, Pal   +6 more
openaire   +2 more sources